

Carmen Criscitiello

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1947155/publications.pdf>

Version: 2024-02-01

99
papers

7,034
citations

109137

35
h-index

62479

80
g-index

100
all docs

100
docs citations

100
times ranked

10856
citing authors

#	ARTICLE	IF	CITATIONS
1	Immunotherapy in Breast Cancer Patients: A Focus on the Use of the Currently Available Biomarkers in Oncology. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2022, 22, 787-800.	0.9	25
2	Targeting brain metastases in breast cancer. <i>Cancer Treatment Reviews</i> , 2022, 103, 102324.	3.4	46
3	Evolution of low HER2 expression between early and advanced-stage breast cancer. <i>European Journal of Cancer</i> , 2022, 163, 35-43.	1.3	88
4	HER2 Low, Ultra-low, and Novel Complementary Biomarkers: Expanding the Spectrum of HER2 Positivity in Breast Cancer. <i>Frontiers in Molecular Biosciences</i> , 2022, 9, 834651.	1.6	63
5	How I treat HER2-positive early breast cancer: how long adjuvant trastuzumab is needed?. <i>ESMO Open</i> , 2022, 7, 100428.	2.0	4
6	A phase III trial of alpelisib+trastuzumab ±fulvestrant versus trastuzumab+ chemotherapy in HER2+ PIK3CA-mutated breast cancer. <i>Future Oncology</i> , 2022, 18, 2339-2349.	1.1	15
7	Immunotherapy for HER2-Positive Breast Cancer: Clinical Evidence and Future Perspectives. <i>Cancers</i> , 2022, 14, 2136.	1.7	21
8	Baseline tumor size as prognostic index in patients with cancer receiving experimental targeted agents.. <i>Journal of Clinical Oncology</i> , 2022, 40, 3063-3063.	0.8	0
9	Antibody-drug conjugates in solid tumors: a look into novel targets. <i>Journal of Hematology and Oncology</i> , 2021, 14, 20.	6.9	129
10	Nipple Sparing Mastectomy as a Risk-Reducing Procedure for BRCA-Mutated Patients. <i>Genes</i> , 2021, 12, 253.	1.0	11
11	PIK3CA Mutations as a Molecular Target for Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 644737.	1.3	70
12	PIK3CA Mutation Assessment in HR+/HER2 ⁻ Metastatic Breast Cancer: Overview for Oncology Clinical Practice. <i>Journal of Molecular Pathology</i> , 2021, 2, 42-54.	0.5	9
13	Body mass index, adiposity and tumour infiltrating lymphocytes as prognostic biomarkers in patients treated with immunotherapy: A multi-parametric analysis. <i>European Journal of Cancer</i> , 2021, 145, 197-209.	1.3	16
14	Immunotherapy addition to neoadjuvant chemotherapy for early triple negative breast cancer: A systematic review and meta-analysis of randomized clinical trials. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 159, 103223.	2.0	52
15	Tucatinib approval by EMA expands options for HER2-positive locally advanced or metastatic breast cancer. <i>ESMO Open</i> , 2021, 6, 100063.	2.0	7
16	Impact of COVID-19 on social media as perceived by the oncology community: results from a survey in collaboration with the European Society for Medical Oncology (ESMO) and the OncoAlert Network. <i>ESMO Open</i> , 2021, 6, 100104.	2.0	15
17	Benefit of adjuvant chemotherapy in patients with special histology subtypes of triple-negative breast cancer: a systematic review. <i>Breast Cancer Research and Treatment</i> , 2021, 187, 323-337.	1.1	15
18	Managing side effects of immune checkpoint inhibitors in breast cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 162, 103354.	2.0	15

#	ARTICLE	IF	CITATIONS
19	Benefit of adjuvant chemotherapy in patients with lobular breast cancer: A systematic review of the literature and metanalysis. <i>Cancer Treatment Reviews</i> , 2021, 97, 102205.	3.4	21
20	Should oncoplastic breast conserving surgery be used for the treatment of early stage breast cancer? Using the GRADE approach for development of clinical recommendations. <i>Breast</i> , 2021, 57, 25-35.	0.9	20
21	Breast Cancer with Bone Metastasis: Molecular Insights and Clinical Management. <i>Cells</i> , 2021, 10, 1377.	1.8	35
22	Antibody-drug conjugates, immune-checkpoint inhibitors, and their combination in breast cancer therapeutics. <i>Expert Opinion on Biological Therapy</i> , 2021, 21, 945-962.	1.4	26
23	Breast reconstruction and radiation therapy: An Italian expert Delphi consensus statements and critical review. <i>Cancer Treatment Reviews</i> , 2021, 99, 102236.	3.4	7
24	Clinical outcomes of patients with metastatic breast cancer enrolled in phase I clinical trials. <i>European Journal of Cancer</i> , 2021, 157, 40-49.	1.3	3
25	Safety of COVID-19 mRNA Vaccines in Patients with Cancer Enrolled in Early-Phase Clinical Trials. <i>Cancers</i> , 2021, 13, 5829.	1.7	8
26	Efficacy of Antiresorptive Drugs on Bone Mineral Density in Post-Menopausal Women With Early Breast Cancer Receiving Adjuvant Aromatase Inhibitors: A Systematic Review of Randomized Controlled Trials. <i>Frontiers in Oncology</i> , 2021, 11, 829875.	1.3	19
27	Assessment of estrogen receptor low positive status in breast cancer: Implications for pathologists and oncologists. <i>Histology and Histopathology</i> , 2021, , 18376.	0.5	11
28	Expression of tumor-associated antigens in breast cancer subtypes. <i>Breast</i> , 2020, 49, 202-209.	0.9	24
29	Association between baseline tumour burden and outcome in patients with cancer treated with next-generation immunoncology agents. <i>European Journal of Cancer</i> , 2020, 139, 92-98.	1.3	12
30	Practical classification of triple-negative breast cancer: intratumoral heterogeneity, mechanisms of drug resistance, and novel therapies. <i>Npj Breast Cancer</i> , 2020, 6, 54.	2.3	181
31	Impact of Rehabilitation on Breast Cancer Related Fatigue: A Pilot Study. <i>Frontiers in Oncology</i> , 2020, 10, 556718.	1.3	49
32	Adjuvant treatment of early male breast cancer. <i>Current Opinion in Oncology</i> , 2020, 32, 594-602.	1.1	6
33	Pretreatment Blood Parameters Predict Efficacy from Immunotherapy Agents in Early Phase Clinical Trials. <i>Oncologist</i> , 2020, 25, e1732-e1742.	1.9	16
34	Incidental thyroid papillary microcarcinoma on 1777 surgically treated patients for benign thyroid disease. <i>Memo - Magazine of European Medical Oncology</i> , 2020, 13, 126-133.	0.3	1
35	Early Triple Negative Breast Cancer: Conventional Treatment and Emerging Therapeutic Landscapes. <i>Cancers</i> , 2020, 12, 819.	1.7	61
36	Cancer care during the spread of coronavirus disease 2019 (COVID-19) in Italy: young oncologistsâ€™ perspective. <i>ESMO Open</i> , 2020, 5, e000759.	2.0	161

#	ARTICLE	IF	CITATIONS
37	PTEN Alterations and Their Role in Cancer Management: Are We Making Headway on Precision Medicine?. <i>Genes</i> , 2020, 11, 719.	1.0	67
38	Tumor-infiltrating lymphocytes (TILs) in ER+/HER2- breast cancer. <i>Breast Cancer Research and Treatment</i> , 2020, 183, 347-354.	1.1	59
39	Tumour infiltrating lymphocytes and correlation with response to intensified platinum-based chemotherapy in BRCA-like tumours. <i>European Journal of Cancer</i> , 2020, 127, 236-239.	1.3	3
40	Inclusion of Platinum Agents in Neoadjuvant Chemotherapy Regimens for Triple-Negative Breast Cancer Patients: Development of GRADE (Grades of Recommendation, Assessment, Development and) Tj ETQq0 0 0,rgBT /Overlock 10 T 1137.	1.78	22
41	Predictive and prognostic value of stromal tumour-infiltrating lymphocytes before and after neoadjuvant therapy in triple negative and HER2-positive breast cancer. <i>European Journal of Cancer</i> , 2019, 118, 41-48.	1.3	48
42	Development of Personalized Therapeutic Strategies by Targeting Actionable Vulnerabilities in Metastatic and Chemotherapy-Resistant Breast Cancer PDXs. <i>Cells</i> , 2019, 8, 605.	1.8	12
43	Treatment in real-life patients with HER2-positive metastatic breast cancer: What we learn from the KAMILLA trial?. <i>European Journal of Cancer</i> , 2019, 117, 1-4.	1.3	2
44	Peptide vaccines in early breast cancer. <i>Breast</i> , 2019, 44, 128-134.	0.9	12
45	WDR5 inhibition halts metastasis dissemination by repressing the mesenchymal phenotype of breast cancer cells. <i>Breast Cancer Research</i> , 2019, 21, 123.	2.2	31
46	Harmonizing gene signatures to predict benefit from adjuvant chemotherapy in early breast cancer. <i>Current Opinion in Oncology</i> , 2019, 31, 472-479.	1.1	3
47	Prognostic value of tumor-infiltrating lymphocytes in patients with early-stage triple-negative breast cancers (TNBC) who did not receive adjuvant chemotherapy. <i>Annals of Oncology</i> , 2019, 30, 1941-1949.	0.6	155
48	A clinical perspective on escalating or de-escalating adjuvant therapy in HER2+ breast cancer. <i>Expert Review of Clinical Pharmacology</i> , 2019, 12, 9-16.	1.3	4
49	Toward precision medicine in inflammatory breast cancer. <i>Translational Cancer Research</i> , 2019, 8, S469-S478.	0.4	4
50	Clinical efficacy of ribociclib as a first-line therapy for HR-positive, advanced breast cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 299-305.	0.9	4
51	The use of breast imaging for predicting response to Neoadjuvant lapatinib, trastuzumab and their combination in HER2-positive breast cancer: Results from Neo-ALTT0. <i>European Journal of Cancer</i> , 2018, 89, 42-48.	1.3	13
52	ESMO Leaders Generation Programme: an alumni insight. <i>ESMO Open</i> , 2018, 3, e000312.	2.0	0
53	A gene signature to predict high tumor-infiltrating lymphocytes after neoadjuvant chemotherapy and outcome in patients with triple-negative breast cancer. <i>Annals of Oncology</i> , 2018, 29, 162-169.	0.6	46
54	CDK4/6 inhibitors in the treatment of patients with breast cancer: summary of a multidisciplinary round-table discussion. <i>ESMO Open</i> , 2018, 3, e000368.	2.0	35

#	ARTICLE	IF	CITATIONS
55	Impact of neoadjuvant chemotherapy and pathological complete response on eligibility for breast-conserving surgery in patients with early breast cancer: A meta-analysis. <i>European Journal of Cancer</i> , 2018, 97, 1-6.	1.3	35
56	Cancer Immunotherapy and Identification of Prognostic and Predictive Biomarkers. <i>BioMed Research International</i> , 2018, 2018, 1-2.	0.9	3
57	Profile of buparlisib and its potential in the treatment of breast cancer: evidence to date. <i>Breast Cancer: Targets and Therapy</i> , 2018, Volume 10, 23-29.	1.0	15
58	The Impact of Translational Research in Breast Cancer Care: Can we Improve the Therapeutic Scenario?. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2018, 18, 832-836.	0.9	3
59	The Emerging Role of "Liquid Biopsies," Circulating Tumor Cells, and Circulating Cell-Free Tumor DNA in Lung Cancer Diagnosis and Identification of Resistance Mutations. <i>Current Oncology Reports</i> , 2017, 19, 1.	1.8	53
60	Pharmacokinetic drug evaluation of ribociclib for the treatment of metastatic, hormone-positive breast cancer. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2017, 13, 575-581.	1.5	17
61	Extending indication of cyclin-dependent kinase 4/6 inhibitors in the adjuvant and neoadjuvant setting. <i>Current Opinion in Oncology</i> , 2017, 29, 428-433.	1.1	2
62	Entinostat for the treatment of breast cancer. <i>Expert Opinion on Investigational Drugs</i> , 2017, 26, 965-971.	1.9	54
63	Tumor-infiltrating lymphocytes in breast cancer according to tumor subtype: Current state of the art. <i>Breast</i> , 2017, 35, 142-150.	0.9	87
64	Prognostic value of tumour-infiltrating lymphocytes in small HER2-positive breast cancer. <i>European Journal of Cancer</i> , 2017, 87, 164-171.	1.3	7
65	Bowel obstruction and peritoneal carcinomatosis in the elderly. A systematic review. <i>Aging Clinical and Experimental Research</i> , 2017, 29, 73-78.	1.4	19
66	Tumor-infiltrating lymphocytes (TILs) are a powerful prognostic marker in patients with triple-negative breast cancer enrolled in the IBCSG phase III randomized clinical trial 22-00. <i>Breast Cancer Research and Treatment</i> , 2016, 158, 323-331.	1.1	100
67	Somatic mutation, copy number and transcriptomic profiles of primary and matched metastatic estrogen receptor-positive breast cancers. <i>Annals of Oncology</i> , 2016, 27, 1860-1866.	0.6	45
68	Prognostic and predictive value of tumor infiltrating lymphocytes in early breast cancer. <i>Cancer Treatment Reviews</i> , 2016, 50, 205-207.	3.4	50
69	Cardiotoxicity of anticancer treatments: Epidemiology, detection, and management. <i>Ca-A Cancer Journal for Clinicians</i> , 2016, 66, 309-325.	157.7	485
70	Breast conservation following neoadjuvant therapy for breast cancer in the modern era: Are we losing the opportunity?. <i>European Journal of Surgical Oncology</i> , 2016, 42, 1780-1786.	0.5	26
71	What indication, morbidity and mortality for central pancreatectomy in oncological surgery? A systematic review. <i>International Journal of Surgery</i> , 2016, 28, S172-S176.	1.1	20
72	Liquid biopsies for solid tumors: Understanding tumor heterogeneity and real time monitoring of early resistance to targeted therapies. , 2016, 157, 120-124.		86

#	ARTICLE	IF	CITATIONS
73	RNAi screens identify CHD4 as an essential gene in breast cancer growth. <i>Oncotarget</i> , 2016, 7, 80901-80915.	0.8	37
74	Targeting fibroblast growth factor receptor pathway in breast cancer. <i>Current Opinion in Oncology</i> , 2015, 27, 452-456.	1.1	17
75	Immunosuppression and Multiple Primary Malignancies in Kidney-Transplanted Patients: A Single-Institute Study. <i>BioMed Research International</i> , 2015, 2015, 1-8.	0.9	20
76	Immunotherapy of Breast Cancer. <i>Progress in Tumor Research</i> , 2015, 42, 30-43.	0.1	27
77	Crosstalk between bone niche and immune system: Osteoimmunology signaling as a potential target for cancer treatment. <i>Cancer Treatment Reviews</i> , 2015, 41, 61-68.	3.4	48
78	Surgery of the primary tumor in de novo metastatic breast cancer: To do or not to do?. <i>European Journal of Surgical Oncology</i> , 2015, 41, 1288-1292.	0.5	30
79	Highlights from the 14th St Gallen International Breast Cancer Conference 2015 in Vienna: Dealing with classification, prognostication, and prediction refinement to personalize the treatment of patients with early breast cancer. <i>Ecancermedicalscience</i> , 2015, 9, 518.	0.6	50
80	Neoadjuvant Model for Testing Emerging Targeted Therapies in Breast Cancer. <i>Journal of the National Cancer Institute Monographs</i> , 2015, 2015, 51-55.	0.9	8
81	Mechanisms of anorexia/cachexia syndrome and rationale for treatment with selective ghrelin receptor agonist. <i>Cancer Treatment Reviews</i> , 2015, 41, 793-797.	3.4	27
82	The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. <i>Annals of Oncology</i> , 2015, 26, 259-271.	0.6	2,122
83	Barriers to the Use of Trastuzumab for HER2+ Breast Cancer and the Potential Impact of Biosimilars: A Physician Survey in the United States and Emerging Markets. <i>Pharmaceuticals</i> , 2014, 7, 943-953.	1.7	69
84	Factors affecting surgical management following neoadjuvant therapy in patients with primary HER2-positive breast cancer: results from the NeoALTTO phase III trial. <i>Annals of Oncology</i> , 2014, 25, 910-911.	0.6	7
85	Immune Checkpoint Blockade in Cancer Treatment: A Double-Edged Sword Cross-Targeting the Host as an "Innocent Bystander". <i>Toxins</i> , 2014, 6, 914-933.	1.5	62
86	Cardiotoxicity of systemic agents used in breast cancer. <i>Breast</i> , 2014, 23, 317-328.	0.9	49
87	Dendritic cell-based vaccines: clinical applications in breast cancer. <i>Immunotherapy</i> , 2014, 6, 349-360.	1.0	38
88	High Ki-67 score is indicative of a greater benefit from adjuvant chemotherapy when added to endocrine therapy in Luminal B HER2 negative and node-positive breast cancer. <i>Breast</i> , 2014, 23, 69-75.	0.9	92
89	No Link between Breast Cancer and Meningioma: Results from a Large Monoinstitutional Retrospective Analysis. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014, 23, 215-217.	1.1	11
90	Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study. <i>Annals of Oncology</i> , 2014, 25, 611-618.	0.6	359

#	ARTICLE	IF	CITATIONS
91	Factors associated with surgical management following neoadjuvant therapy in patients with primary HER2-positive breast cancer: results from the NeoALTTO phase III trial. <i>Annals of Oncology</i> , 2013, 24, 1980-1985.	0.6	32
92	HER2 signaling pathway and trastuzumab cardiotoxicity. <i>Future Oncology</i> , 2013, 9, 179-181.	1.1	14
93	Adverse prognostic impact of intratumor heterogeneous HER2 gene amplification in patients with breast cancer.. <i>Journal of Clinical Oncology</i> , 2013, 31, 617-617.	0.8	0
94	Second primary tumors in cancer patients: A retrospective analysis based on institutional tumor registry.. <i>Journal of Clinical Oncology</i> , 2013, 31, 1595-1595.	0.8	0
95	Tumor-Associated Antigens in Breast Cancer. <i>Breast Care</i> , 2012, 7, 262-266.	0.8	56
96	Gene Modules and Response to Neoadjuvant Chemotherapy in Breast Cancer Subtypes: A Pooled Analysis. <i>Journal of Clinical Oncology</i> , 2012, 30, 1996-2004.	0.8	194
97	Targeted therapies in breast cancer: are heart and vessels also being targeted?. <i>Breast Cancer Research</i> , 2012, 14, 209.	2.2	24
98	Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines. <i>Annals of Oncology</i> , 2012, 23, vii155-vii166.	0.6	667
99	Circulating tumor cells and emerging blood biomarkers in breast cancer. <i>Current Opinion in Oncology</i> , 2010, 22, 552-558.	1.1	46